A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrent High-Grade Glioma Undergoing Standard. Repeated Temozolomide Treatment (TAU-2010-1)

Grant

Date/time Interval

  • November 1, 2013 - December 31, 2018
  • Total Award Amount

  • 8000.00
  • Direct Costs

  • 5442.00
  • Sponsor Award Id

  • ABTC 1101
  • Contributor

  • Fathallah-Shaykh M.D., Ph.D., Hassan   Investigator  
  • Han, Xiaosi   Investigator  
  • Nabors M.D., Louis   Principal Investigator